Abstract
Background: Non-Hodgkin's lymphomas (NHL), derived from B- or T-cell, consist of a heterogeneous group of malignant lymphoproliferative disorders. Knockdown of Casein kinase 2 interacting protein-1 (CKIP-1) in NHL promoted cell proliferation and inhibited apoptosis via enhancing phosphorylated Protein Kinase B (PKB or AKT) expression. Statins are the class of drugs that inhibit the ratelimiting step of the mevalonate pathway, which is essential for the biosynthesis of various compounds, including cholesterol. Also, statins have anticancer properties being mediated by different mechanisms.
Methods: A search on databases like Scopus and PubMed with keywords such as statin and non- Hodgkin's lymphomas was performed and Kyoto Encyclopedia of Genes and Genomes (KEGG) website was used to evaluate and reconfirm the involved cellular signaling pathway.
Results: CKIP-1 is involved in the regulation of cell proliferation and apoptosis while plays an important role in many cancers. We can hypothesize that statins may increase the expression levels of CKIP-1 which could contribute to the reductions in phospho-AKT level. Hence, they may ameliorate the NHL patients via suppressing AKT phosphorylation and increasing CKIP- expression.
Conclusion: Present review confirms the positive effect of statins on NHL by increasing CKIP-1 and reducing cell proliferation, subsequently.
Keywords: Statin, CKIP, AKT, non-hodgkin's lymphomas, apoptosis, signaling pathway.
Current Drug Discovery Technologies
Title:Statins as the Controlling Agents for Non-Hodgkin's Lymphomas via Increasing the Casein Kinase 2 Interacting Protein-1: A Hypothesis
Volume: 17 Issue: 5
Author(s): Kimia Kazemi, Negin Mozafari, Hajar Ashrafi, Pedram Rafiei and Amir Azadi*
Affiliation:
- Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz,Iran
Keywords: Statin, CKIP, AKT, non-hodgkin's lymphomas, apoptosis, signaling pathway.
Abstract:
Background: Non-Hodgkin's lymphomas (NHL), derived from B- or T-cell, consist of a heterogeneous group of malignant lymphoproliferative disorders. Knockdown of Casein kinase 2 interacting protein-1 (CKIP-1) in NHL promoted cell proliferation and inhibited apoptosis via enhancing phosphorylated Protein Kinase B (PKB or AKT) expression. Statins are the class of drugs that inhibit the ratelimiting step of the mevalonate pathway, which is essential for the biosynthesis of various compounds, including cholesterol. Also, statins have anticancer properties being mediated by different mechanisms.
Methods: A search on databases like Scopus and PubMed with keywords such as statin and non- Hodgkin's lymphomas was performed and Kyoto Encyclopedia of Genes and Genomes (KEGG) website was used to evaluate and reconfirm the involved cellular signaling pathway.
Results: CKIP-1 is involved in the regulation of cell proliferation and apoptosis while plays an important role in many cancers. We can hypothesize that statins may increase the expression levels of CKIP-1 which could contribute to the reductions in phospho-AKT level. Hence, they may ameliorate the NHL patients via suppressing AKT phosphorylation and increasing CKIP- expression.
Conclusion: Present review confirms the positive effect of statins on NHL by increasing CKIP-1 and reducing cell proliferation, subsequently.
Export Options
About this article
Cite this article as:
Kazemi Kimia , Mozafari Negin , Ashrafi Hajar , Rafiei Pedram and Azadi Amir *, Statins as the Controlling Agents for Non-Hodgkin's Lymphomas via Increasing the Casein Kinase 2 Interacting Protein-1: A Hypothesis, Current Drug Discovery Technologies 2020; 17 (5) . https://dx.doi.org/10.2174/1570163816666190628165200
DOI https://dx.doi.org/10.2174/1570163816666190628165200 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
Call for Papers in Thematic Issues
Advancements in Computational Methods for Drug Design
This thematic issue delves into the cutting-edge computational methodologies revolutionizing drug design. Emphasizing the integration of in silico techniques, this collection highlights advancements in some computational methods, as: molecular docking, molecular dynamics, QSAR (Quantitative Structure-Activity Relationship) and free energy calculations. These approaches enhance the efficiency of drug discovery, reduce costs, ...read more
Disease Modelling: Emerging Frontiers in Disease Modelling: Data to Drug Discovery in Bioinformatics in Precision Medicine and Health Science
The special issue on "Emerging Frontiers in Disease Modelling: Data to Drug Discovery in Bioinformatics in Precision Medicine and Health Science" aims to explore the transformative role of bioinformatics in bridging the gap between extensive biological data and the development of targeted therapies. This issue will highlight cutting-edge research and ...read more
Novel drug delivery therapeutics: Opportunities and challenges for combating diseases
The field of drug delivery therapeutics has undergone significant transformation with the emergence of innovative technologies designed to enhance therapeutic efficacy and patient outcomes. As traditional drug administration methods encounter limitations in terms of efficacy, safety, and patient compliance, novel drug delivery systems offer promising solutions to these challenges. Advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-tumor Therapeutic Molecules that Target the Programmed Cell Death Machinery
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
Reviews on Recent Clinical Trials Recognition of Nucleic Acids by Toll-Like Receptors and Development of Immunomodulatory Drugs
Current Medicinal Chemistry An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Recent Developments Towards the Synthesis of Varitriol: An Antitumour Agent from Marine Derived Fungus Emericella Variecolor
Current Organic Synthesis Current Technological Development of Antibody Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Applications of Targeting Anti-Cancer Agents in Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Current Gene Therapy Strategies for Colorectal Cancer
Current Genomics Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Transition Metal-Based Prodrugs for Anticancer Drug Delivery
Current Medicinal Chemistry Cox Inhibitors as Potential Chemotherapic Drugs for Mesothelioma
Current Respiratory Medicine Reviews Review on Triggered Liposomal Drug Delivery with a Focus on Ultrasound
Current Cancer Drug Targets In vivo Radiosensitization of Human Glioma U87 Cells Induced by Upregulated Expression of DUSP-2 after Treatment with Curcumin
Current Signal Transduction Therapy Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design The Use of Cytokines and Chemokines in the Cancer Immunotherapy
Recent Patents on Anti-Cancer Drug Discovery Targeting Aurora Kinases in Cancer Treatment
Current Drug Targets Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids
Current Topics in Medicinal Chemistry Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design